Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2015

View Archived Issues

BI-655066 superior to ustekinumab as a short-term treatment for moderate to severe psoriasis

Synthetic Biologics begins phase IIa trial of SYN-004

Cell Therapy Catapult signs collaborative agreements in regenerative medicine

Taisho and Teijin sign Japanese marketing agreement for TT-063 patch

Pan-opioid receptor antagonist developed at Astraea Therapeutics

Thrasos Therapeutics secures funds to complete phase II study of THR-184

CT-1812: Lead candidate from CogRx in sigma-2/PGRMC1 antagonism approach

Kissei and Ajinomoto enter into partnership for AJM-300 and AJG-511 in Japan

Syndax and Merck & Co. to collaborate on study of entinostat plus Keytruda

ESSA Pharma files IND application for androgen receptor inhibitor

The Institute of Cancer Research patents PARP and Wnt inhibitors

Cortendo report new cytochrome P450 inhibtors

Mitsubishi Tanabe to develop Neurocrine Biosciences' NBI-98854 in Asia

Bioengineered human muscle shows potential as a platform for drug development and disease modeling

RedHill Biopharma acquires Apogee Biotech's ABC-294640

Biotie begins enrollment in phase IIa study of BTT-1023 in primary sclerosing cholangitis

Sigma-Tau Pharmaceuticals' STP-206 receives FDA orphan drug designation

FDA grants orphan drug designation to IMO-8400 for diffuse large B-cell lymphoma

Phase II study of gevokizumab in patients with diabetic nephropathy begins

LDC and HZI partner on MRSA drug discovery

Phylogica's CPP fusions kill drug-resistant breast cancer cells

Aeterna Zentaris to transfer discovery library to Medical University of South Carolina

Valeant completes acquisition of Salix

Kowa discloses PCSK9 mRNA expression inhibitors

Actelion patents indazole antibacterials

Ocera Therapeutics reports interim analysis of OCR-002 study in acute hepatic encephalopathy

Teva to acquire Auspex Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...